Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.

Martin P, Dirks B, Gertsik L, Walling D, Stevenson A, Corcoran M, Raychaudhuri A, Ermer J.

J Clin Psychopharmacol. 2014 Dec;34(6):682-9. doi: 10.1097/JCP.0000000000000205.

PMID:
25310201
3.

An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults.

Ermer J, Haffey MB, Richards C, Lasseter K, Roesch B, Purkayastha J, Corcoran M, Harlin B, Martin P.

Clin Drug Investig. 2013 Apr;33(4):243-54. doi: 10.1007/s40261-013-0073-1.

4.

Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults.

Ermer J, Haffey MB, Richards C, Lasseter K, Adeyi B, Corcoran M, Stanton B, Martin P.

Neuropsychiatr Dis Treat. 2013;9:219-29. doi: 10.2147/NDT.S38377. Epub 2013 Feb 12.

5.

Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.

Ermer J, Homolka R, Martin P, Buckwalter M, Purkayastha J, Roesch B.

J Clin Pharmacol. 2010 Sep;50(9):1001-10. doi: 10.1177/0091270009357346. Epub 2010 Feb 19.

PMID:
20173084
6.

Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.

Haffey MB, Buckwalter M, Zhang P, Homolka R, Martin P, Lasseter KC, Ermer JC.

Postgrad Med. 2009 Sep;121(5):11-9. doi: 10.3810/pgm.2009.09.2048.

PMID:
19820270
9.

Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults.

Ermer JC, Haffey MB, Doll WJ, Martin P, Sandefer EP, Dennis K, Corcoran M, Trespidi L, Page RC.

Drug Metab Dispos. 2012 Feb;40(2):290-7. doi: 10.1124/dmd.111.040691. Epub 2011 Oct 28.

PMID:
22039171
11.

Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.

Lasser RA, Dirks B, Nasrallah H, Kirsch C, Gao J, Pucci ML, Knesevich MA, Lindenmayer JP.

Neuropsychopharmacology. 2013 Oct;38(11):2140-9. doi: 10.1038/npp.2013.111. Epub 2013 May 8.

13.

Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L.

J Am Acad Child Adolesc Psychiatry. 2011 Apr;50(4):395-405. doi: 10.1016/j.jaac.2011.01.007. Epub 2011 Mar 3.

PMID:
21421179
14.

Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.

Ermer JC, Dennis K, Haffey MB, Doll WJ, Sandefer EP, Buckwalter M, Page RC, Diehl B, Martin PT.

Clin Drug Investig. 2011;31(6):357-70. doi: 10.2165/11588190-000000000-00000.

PMID:
21539403
15.

Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.

Roesch B, Corcoran ME, Fetterolf J, Haffey M, Martin P, Preston P, Purkayastha J, Wang P, Ermer J.

Drugs R D. 2013 Jun;13(2):119-28. doi: 10.1007/s40268-013-0014-8.

16.

Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.

Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L.

J Clin Psychiatry. 2012 Jul;73(7):977-83. doi: 10.4088/JCP.11m07430. Epub 2012 Jun 12.

PMID:
22780921
17.

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.

Jasinski DR, Krishnan S.

J Psychopharmacol. 2009 Jun;23(4):419-27. doi: 10.1177/0269881109103113. Epub 2009 Mar 27.

PMID:
19329547
18.

Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers.

Krishnan SM, Stark JG.

Curr Med Res Opin. 2008 Jan;24(1):33-40.

PMID:
18021493
19.

A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.

Ermer J, Corcoran M, Lasseter K, Marbury T, Yan B, Martin PT.

Ther Drug Monit. 2016 Aug;38(4):546-55. doi: 10.1097/FTD.0000000000000296.

20.

Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials.

McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M.

Neuropsychopharmacology. 2016 Apr;41(5):1251-60. doi: 10.1038/npp.2015.275. Epub 2015 Sep 9.

Supplemental Content

Support Center